2022 American Transplant Congress
Sodium-Glucose Co-Transporter 2 Inhibitors; Short-Term Outcome in Diabetic Kidney Transplant Recipients
*Purpose: The idea of using SGLT2i in kidney transplant recipients (KTR) is a legitimate one after the recent encouraging data for their use in other…2022 American Transplant Congress
Outcomes of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Diabetic Kidney Transplant Recipients
*Purpose: The impact of the new glucose lowering therapies, sodium-glucose cotransporter 2 inhibitors (SGLT2i) and Glucagon-like peptide-1 receptor agonists (GLP-1RA), on managing patients with type…2022 American Transplant Congress
Intermediate Term Outcomes of SGLT2 Inhibitors Amongst Diabetic Kidney Transplant Recipients
1Pharmacy, VCUHS, Richmond, VA, 2VCUHS, Richmond, VA
*Purpose: The use of Sodium Glucose Linked Transporter Inhibitors (SGLT-2i) among non-transplant diabetic patients with chronic kidney disease (CKD) has demonstrated reduced cardiovascular mortality, delayed…2022 American Transplant Congress
Cryptococcal Meningitis Presenting as SIADH in a Heart Transplant Recipient
Temple University Hospital, Philadelphia, PA
*Purpose: Cryptococcal meningitis is a potentially fatal invasive fungal infection in solid organ transplant recipients. Meningoencephalitis is the most common clinical manifestation of cryptococcal infection.…2022 American Transplant Congress
Outcomes of Simultaneous Kidney Pancreas Transplantation in Patients with Type-1 and Type-2 Diabetes Mellitus
*Purpose: Advantages for type-2 diabetes mellitus (T2DM) patients receiving simultaneous kidney-pancreas transplantation (SKPT) as compared to kidney transplantation are shorter waiting times and availability of…2022 American Transplant Congress
Steatosis Following Liver Transplantation for Nonalcoholic Steatohepatitis is Associated with a Higher Rate of Cardiovascular Complications
*Purpose: Cirrhosis secondary to Nonalcoholic Steatohepatitis (NASH) is projected to become the leading indication for liver transplantation (LT) worldwide. Objectives: to evaluate the prevalence of…2022 American Transplant Congress
Associations of Immunosuppression Regimen with Fracture Risk After Kidney Transplant in High-Risk Populations: Identifying Targets for Risk-Reduction
*Purpose: Disorders of bone and mineral metabolism frequently develop with advanced kidney disease, may be exacerbated by immunosuppression (ISx) after kidney transplant (KTx), and may…2022 American Transplant Congress
Sodium-Glucose Cotransporter 2 Inhibitors to Treat Diabetes Mellitus After Kidney Transplant
*Purpose: This study describes experience prescribing sodium-glucose cotransport 2 inhibitors (SGLT2i) after kidney transplant to evaluate safety and effectiveness.*Methods: This is a retrospective, institutional review…2022 American Transplant Congress
Recipient TIM4+ Macrophage is a Central Hub for Metabolic Homeostasis in Liver Transplantation: From Mouse-to-Human
*Purpose: Hepatic ischemia-reperfusion injury (IRI) is a major risk factor for early graft dysfunction and predisposes to rejection in orthotopic liver transplantation (OLT). Previous studies…2022 American Transplant Congress
Pegloticase for Uncontrolled Gout in Kidney Transplant Recipients: Provisional Data Report of a Multicenter, Open-Label, Efficacy and Safety Study
*Purpose: Gout in kidney transplant (KT) recipients can be severe and particularly challenging to manage. Pegloticase co-therapy with immunomodulators improved urate lowering therapy (ULT) response…
- 1
- 2
- 3
- …
- 11
- Next Page »